C57BL/6JCya-Cd70em1/Cya
Common Name:
Cd70-KO
Product ID:
S-KO-18123
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Cd70-KO
Strain ID
KOCMP-21948-Cd70-B6J-VB
Gene Name
Product ID
S-KO-18123
Gene Alias
CD27LG; Cd27l; Tnfsf7; Tnlg8a
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
17
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Cd70em1/Cya mice (Catalog S-KO-18123) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000019633
NCBI RefSeq
NM_011617
Target Region
Exon 1~2
Size of Effective Region
~1.7 kb
Detailed Document
Overview of Gene Research
Cd70, also known as CD70 antigen, is an immune checkpoint molecule. Its tightly controlled expression under physiological conditions plays a role in co-stimulation in immune responses. It interacts with its receptor CD27, and the CD70-CD27 axis is involved in multiple biological processes related to the immune system [1].
The CD70-CD27 axis is aberrantly expressed in many hematological and solid malignancies. In hematological malignancies, cancer cells co-express CD70 and CD27, promoting stemness, proliferation, and survival of malignancy. In solid tumors, CD70 expression on tumor cells can facilitate immune evasion through CD27 expression in the tumor microenvironment [1]. In non-small cell lung cancer, CD70 is highly upregulated in EMT-associated resistance to EGFR tyrosine kinase inhibitors, promoting cell survival and invasiveness [2]. Nasopharyngeal carcinoma cells enhance the development and suppressive activity of regulatory T cells via CD70-CD27 interaction, and CD70 blocking can reinvigorate CD8+ T-cell immunity [3]. CD70-targeted allogeneic CAR T-cell therapy shows potential for advanced clear cell renal cell carcinoma [4]. Anti-CD70 CAR-T cells are a potential treatment for acute myeloid leukemia, though they did not completely eliminate leukemia in vivo [5]. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit enhanced antitumor functionality against multiple solid tumors [6]. IL-15-secreting CAR natural killer cells directed toward CD70 can eliminate both cancer cells and cancer-associated fibroblasts [7]. CD70 CAR T cells secreting a bispecific T-cell engaging antibody targeting CD33 can overcome antigen heterogeneity in AML [8]. Anti-CD70 allogeneic CAR T cells targeting renal cell carcinoma show efficacy and safety in pre-clinical studies [9].
In conclusion, Cd70, through its interaction with CD27, is crucial in the dysregulation of the tumor microenvironment in various malignancies. Studies using different models, such as CAR-T cell-based approaches which can be considered as functional knockdown models in a sense, have revealed its role in promoting tumor progression and immunosuppression. These findings highlight Cd70 as a potential therapeutic target in oncology.
References:
1. Flieswasser, Tal, Van den Eynde, Astrid, Van Audenaerde, Jonas, Pauwels, Patrick, Jacobs, Julie. 2022. The CD70-CD27 axis in oncology: the new kids on the block. In Journal of experimental & clinical cancer research : CR, 41, 12. doi:10.1186/s13046-021-02215-y. https://pubmed.ncbi.nlm.nih.gov/34991665/
2. Nilsson, Monique B, Yang, Yan, Heeke, Simon, Le, Xiuning, Heymach, John V. . CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. In Cancer cell, 41, 340-355.e6. doi:10.1016/j.ccell.2023.01.007. https://pubmed.ncbi.nlm.nih.gov/36787696/
3. Gong, Lanqi, Luo, Jie, Zhang, Yu, Dai, Wei, Guan, Xin-Yuan. 2023. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction. In Nature communications, 14, 1912. doi:10.1038/s41467-023-37614-6. https://pubmed.ncbi.nlm.nih.gov/37024479/
4. Pal, Sumanta K, Tran, Ben, Haanen, John B A G, Agarwal, Neeraj, Srour, Samer A. . CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. In Cancer discovery, 14, 1176-1189. doi:10.1158/2159-8290.CD-24-0102. https://pubmed.ncbi.nlm.nih.gov/38583184/
5. Wu, Gongqiang, Guo, Shanshan, Luo, Qian, Lei, Wen, Qian, Wenbin. 2023. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. In Frontiers in immunology, 14, 1093750. doi:10.3389/fimmu.2023.1093750. https://pubmed.ncbi.nlm.nih.gov/36845088/
6. Yang, Meijia, Tang, Xin, Zhang, Zongliang, Zhou, Liangxue, Tong, Aiping. 2020. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. In Theranostics, 10, 7622-7634. doi:10.7150/thno.43991. https://pubmed.ncbi.nlm.nih.gov/32685008/
7. Van den Eynde, Astrid, Gehrcken, Laura, Verhezen, Tias, Smits, Evelien, Van Audenaerde, Jonas R M. 2024. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. In Journal of hematology & oncology, 17, 8. doi:10.1186/s13045-024-01525-w. https://pubmed.ncbi.nlm.nih.gov/38331849/
8. Silva, Harrison J, Martin, Grace, Birocchi, Filippo, Maus, Marcela V, Leick, Mark B. . CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML. In Blood, 145, 720-731. doi:10.1182/blood.2023023210. https://pubmed.ncbi.nlm.nih.gov/39571145/
9. Panowski, Siler H, Srinivasan, Surabhi, Tan, Nguyen, Chaparro-Riggers, Javier, Sasu, Barbra J. . Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. In Cancer research, 82, 2610-2624. doi:10.1158/0008-5472.CAN-21-2931. https://pubmed.ncbi.nlm.nih.gov/35294525/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen